Target intelligence / Profile preview

Tripartite motif-containing protein 26 (TRIM26)

Target
TRIM26
Molecular classification
E3 ubiquitin-protein ligase, Tripartite motif (TRIM) protein, Other
01

Overview

Tripartite motif-containing protein 26 (TRIM26) is an E3 ubiquitin-protein ligase and a member of the TRIM family, characterized by a RING domain, one or two B-Box domains, a coiled-coil region, and a C-terminal PRY/SPRY domain[1][2][5]. TRIM26 regulates multiple cellular processes, including antiviral innate immunity through modulation of interferon pathways, type I interferon response, and NF-κB/MAPK signaling[1][2][3][5]. It mediates ubiquitination and proteasomal degradation of key immune regulators (such as IRF3, TAB1) and tissue-specific transcription factors (e.g., C/EBPδ), thereby influencing responses to viral infections and inflammation[1][2][3][4][5]. TRIM26 displays both protective and pathogenic roles during infection, inflammation, tumorigenesis, and metabolic disease—actions contextually dependent on cell type and tissue[1][2][3]. It is considered a putative therapeutic target in antiviral, anti-inflammatory, and antifibrotic strategies, but its dual regulatory roles pose challenges for clinical exploitation[1][3][5].

Other names
RNF95ZNF173Acid finger proteinRING finger protein 95Zinc finger protein 173Widely expressed acid zinc finger protein
02

Mechanism of action

Ubiquitination and proteasomal degradation of target proteins (e.g., IRF3, C/EBPδ, PHF20, SLC7A11, TAB1) Modulation of viral protein stability (e.g., HCV NS5B, HBV HBx) Regulation of signaling complexes (e.g., bridging TBK1 and NEMO)

03

Biological functions

Ubiquitination and protein degradationRegulation of antiviral immune response (innate immunity)Regulation of type I interferon productionRegulation of inflammation (NF-κB, MAPK signaling)DNA repair (via modulation of DNA glycosylases)Regulation of cell proliferation and cell death (including ferroptosis)Tumor suppression and modulation of metabolic homeostasis
04

Disease associations

Cancer (tumorigenesis, tumor suppression)Liver diseases (especially non-alcoholic steatohepatitis, NASH)Infection (notably hepatitis B and C virus, herpes simplex virus)InflammationFibrosis
05

Safety considerations

Dual roles in immune response: Can either enhance or suppress antiviral immunity depending on context, raising concerns for therapeutic targeting[1][2][3].Potential impact on inflammation and fibrosis may represent a therapeutic challenge in chronic liver diseases[3].
06

Biomarkers

TRIM26 expression (prognostic in hepatic diseases and inflammation[NASH])Possibly as a marker of antiviral response in viral hepatitis

Beyond the preview

Go deeper on Tripartite motif-containing protein 26 (TRIM26).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tripartite motif-containing protein 26 (TRIM26).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call